Clinical Trial

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Study acronym: KYLIN-1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-26; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT06343064
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small-Cell Lung Cancer
Enrollment 156 participants
Start Date 2023-06-13
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-21